Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)
Release Date:
2026-06-22 12:11
HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.
Donor Selection Practices in Different Tumor Models
Hycells is in NPG mouse model In China, systematic screening and validation of PBMC donors have been conducted for multiple tumor indications.
1. Hep G2 hepatocellular carcinoma CDX Model — Screening successful, model stable
The Hep G2 model likewise validated the reliability of the selected PBMCs—immune reconstitution was successful, tumor infiltration was robust, and the model demonstrated stable performance.
PBMC Donor Screening in Hep G2
Liver Cancer CDX Model with NPG Mice
Immune Cells Reconstitution in PB
Immune Cells Infiltration in Tumors
2. YCC-2 Gastric Cancer CDX Model—Severe Cachexia, Failed Immune Reconstitution
In this donor, the recipient mice developed severe cachexia, and no robust engraftment of human‑derived immune cells was detected in either the peripheral blood or the tumor tissue. This case also demonstrates that PBMC donors who have not undergone rigorous screening not only fail to establish an effective model but may also result in complete experimental failure due to GvHD, cachexia, or other confounding factors.
PBMC Donor Screening in YCC-2 Gastric Cancer CDX Model with NPG Mice
3. HCC 95 lung cancer CDX model—screening successful; model establishment is ongoing.
PBMC Donor Screening in HCC 95 Lung Cancer CDX Model with NPG Mice
Immune Cells Reconstitution in PB
Hycells continues to expand the validation of his preferred PBMCs across an increasing number of tumor types…
If you are facing challenges such as the short window period and high data variability in huPBMC models, please feel free to contact the Hycells technical team. Based on your specific tumor model and drug type, we will provide expert guidance on donor‑screening strategies and in vitro pre‑matching services. In addition, Hycells offers a well‑stocked inventory of premium‑quality PBMC batches for modeling; scan the QR code below to request a trial shipment of cryopreserved PBMCs. Once the mouse strain is confirmed, we will reach out to recommend an optimal huPBMC batch for your assay.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board